How MRI and OCT are Changing Multiple Sclerosis Diagnosis, Prognosis, and Treatment
Om avsnittet
Imaging techniques in multiple sclerosis are evolving rapidly, with MRI and emerging biomarkers playing a central role in diagnosis, prognosis and disease monitoring.
In this episode of the ECTRIMS Podcast, neurologist Gabriel Bsteh and host Brett Drummond explore how MRI, optical coherence tomography (OCT), and imaging biomarkers are reshaping the way clinicians diagnose and manage MS.
They discuss the 2024 updates to the McDonald diagnostic criteria, including the introduction of the central vein sign (CVS), paramagnetic rim lesions (PRL), and the inclusion of the optic nerve.
The episode also examines how imaging biomarkers may be used to:
- Predict disease progression
- Provide prognostic information at diagnosis
- Monitor neuro-axonal damage over time
- Support treatment decisions and personalised medicine
This episode is essential listening for anyone interested in multiple sclerosis, MRI, OCT, biomarkers, and advances in MS research and care.
----------------------------
This ECTRIMS podcast episode is supported by an educational grant from Alexion, AstraZeneca Rare Diseases. Bristol Myers Squibb, Novartis, Roche, Sanofi, and UCB. Educational grant providers have no input into the podcast series content.
Fler avsnitt
Visa alla avsnitt av The ECTRIMS PodcastThe ECTRIMS Podcast med The European Committee for Treatment and Research in Multiple Sclerosis finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.